Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

OncLive June 2011 FDA Digest

June 23rd 2011

FDA digest from June discussing warning labels, pancreatic treatment choices, and the quest for a lymphoma drug.

Surgical Oncologists Typically Follow Treatment Guidelines

June 22nd 2011

A vast majority of Medicare patients with cancer are receiving appropriate surgical care that is in line with current treatment guidelines.

Dr. Vogelzang Describes Cabozantinib's Side Effects

June 21st 2011

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Heavy Beer Drinking Increases Risk of Gastric Cancer

June 20th 2011

Investigators in a large cohort study reported that heavy alcohol consumption, particularly beer, significantly increases the risk of gastric cancer.

Dr. Kris Discusses the Imatinib GIST Clinical Trial

June 20th 2011

Dr. Kris From Memorial Sloan-Kettering Cancer Center Discusses the Imatinib GIST Clinical Trial

Socioeconomic Status Bears Little Impact on Survival Rates

June 10th 2011

Primary cancers of the lung, esophagus, and pancreas-all of which have a poor prognosis-account for >35% of all cancer deaths in the United States annually

Dr. Joensuu Discusses the Progress of GIST Treatments

June 8th 2011

Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses the Progress of gastrointestinal stromal tumors (GIST) Treatments

Three-Year Imatinib Regimen Delivers Optimal GIST Treatment

June 6th 2011

3 years of treatment with imatinib (Gleevec) after surgery in patients with high-risk GIST improved overall and recurrence-free survival

Dr. Joensuu on the Imatinib for High-Risk GIST Trial

June 4th 2011

Dr. Heikki Joensuu from the Helsinki University Central Hospital Summarizes the Imatinib for High-Risk high-risk gastrointestinal stromal tumors (GIST) Trial

Janet Hampton Explains the Distress Thermometer Study

May 24th 2011

Janet Hampton from the University of Michigan Health System Cancer Center Explains the Distress Thermometer Study

Janet Hampton on the Distress Thermometer Study Results

May 24th 2011

Janet Hampton University of Michigan Health System Cancer Center Explains Distress Thermometer Study Results

FDA Approves Sutent for Pancreatic Cancer

May 23rd 2011

The FDA has approved Sutent (sunitinib) for the treatment of patients with unresectable, locally advanced, or metastatic pancreatic neuroendocrine tumors (pNET)

Janet Hampton Describes the Distress Thermometer

May 23rd 2011

Janet Hampton Describes the Distress Thermometer

Four-Drug Chemotherapy Combo Extends Lives of Patients with Pancreatic Cancer

May 12th 2011

Results from a phase III study showed that the chemotherapy combination FOLFIRINOX nearly doubled the survival time for patients with pancreatic adenocarcinoma

Cancer Cells Outsmarting Smart Bombs: Gastrointestinal Stromal Tumors (GIST)

May 12th 2011

Certain patients whose cancer cells form mutations and build up a resistance to drugs, drive the need for second- and third-line therapies

Oncolytic Viruses Target Pancreatic Stem Cells

May 10th 2011

Oncolytic viruses have the potential of killing cancer stem cells, particularly in cases of potentially fatal pancreatic cancer

FDA Approves Afinitor for Pancreatic Cancer

May 6th 2011

Afinitor is now approved for the treatment of pancreatic neuroendocrine tumors in patients with unresectable, locally advanced, or metastatic disease

Two or More Drinks a Day Increases Colorectal Cancer Risk

May 6th 2011

New data suggest that individuals who drink moderate amounts of alcohol have an increased likelihood of developing colorectal cancer

Speculating Spectrum: More buzz about stock prices than the recently approved Fusilev indication

May 5th 2011

Spectrum Pharmaceuticals stock prices are the biggest story across the internet, not the FDA's approval of Fusilev

Aflibercept Delivers Positive Results in Colorectal Trial

April 29th 2011

Aflibercept, an investigational angiogenesis inhibitor, improved overall survival as a second-line treatment for patients with mCRC